Cargando…

Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials

BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conju...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Min, He, Fazhong, Yang, Yang, Lin, Weijie, Qiu, Wentao, Meng, Qian, Zhang, Jianping, Zhou, Zhiling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047954/
https://www.ncbi.nlm.nih.gov/pubmed/33144336
http://dx.doi.org/10.1136/ejhpharm-2020-002447
_version_ 1784695835161788416
author Zhao, Min
He, Fazhong
Yang, Yang
Lin, Weijie
Qiu, Wentao
Meng, Qian
Zhang, Jianping
Zhou, Zhiling
author_facet Zhao, Min
He, Fazhong
Yang, Yang
Lin, Weijie
Qiu, Wentao
Meng, Qian
Zhang, Jianping
Zhou, Zhiling
author_sort Zhao, Min
collection PubMed
description BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis. METHODS: Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis. RESULTS: A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD −1.39, 95% CI −2.50 to −0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD −0.92, 95% CI −1.59 to −0.24; p<0.05) than the control group. CONCLUSION: Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis.
format Online
Article
Text
id pubmed-9047954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90479542022-05-11 Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials Zhao, Min He, Fazhong Yang, Yang Lin, Weijie Qiu, Wentao Meng, Qian Zhang, Jianping Zhou, Zhiling Eur J Hosp Pharm Systematic Review BACKGROUND AND OBJECTIVE: Tacrolimus has been widely used in recent years for treating allergic conjunctivitis, but there is currently no available meta-analysis regarding its therapeutic efficacy. This study systematically evaluated the effectiveness of tacrolimus in the treatment of allergic conjunctivitis. METHODS: Data obtained from literature searches of the PubMed, Cochrane Library, Embase, CNKI, and Wanfang databases were retrieved by combining medical subject words and free words. Literature was selected on the basis of established inclusion and exclusion criteria, and the extracted data were evaluated for risk of bias using RevMan 5.3 for meta-analysis. RESULTS: A total of 177 articles were retrieved, of which 5 articles were eventually selected, all of which involved tacrolimus treatment for vernal keratoconjunctivitis. A total of 203 samples were analysed. Results of the meta-analysis showed that the tacrolimus treatment group had significantly lower ocular objective sign scores (SMD −1.39, 95% CI −2.50 to −0.27; p<0.05) and had a significantly lower subjective symptom evaluation score (SMD −0.92, 95% CI −1.59 to −0.24; p<0.05) than the control group. CONCLUSION: Current evidence shows that tacrolimus is effective in treating vernal keratoconjunctivitis. BMJ Publishing Group 2022-05 2020-11-03 /pmc/articles/PMC9047954/ /pubmed/33144336 http://dx.doi.org/10.1136/ejhpharm-2020-002447 Text en © European Association of Hospital Pharmacists 2022. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Systematic Review
Zhao, Min
He, Fazhong
Yang, Yang
Lin, Weijie
Qiu, Wentao
Meng, Qian
Zhang, Jianping
Zhou, Zhiling
Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title_full Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title_fullStr Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title_full_unstemmed Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title_short Therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
title_sort therapeutic efficacy of tacrolimus in vernal keratoconjunctivitis: a meta-analysis of randomised controlled trials
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047954/
https://www.ncbi.nlm.nih.gov/pubmed/33144336
http://dx.doi.org/10.1136/ejhpharm-2020-002447
work_keys_str_mv AT zhaomin therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT hefazhong therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT yangyang therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT linweijie therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT qiuwentao therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT mengqian therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT zhangjianping therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials
AT zhouzhiling therapeuticefficacyoftacrolimusinvernalkeratoconjunctivitisametaanalysisofrandomisedcontrolledtrials